- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03884556
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- UC Irvine Cancer Center
-
Sacramento, California, United States, 95817
- UC Davis Comprehensive Cancer Center
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Florida
-
Miami, Florida, United States, 33136
- Sylvester Comprehensive Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Center Oncology Hematology West P.C.
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- West Cancer Center and Research Institute
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- NEXT Oncology
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Intitute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Abreviated Inclusion Criteria
Advanced solid tumor malignancy or relapsed/refractory lymphoma, or
- eligible to receive single-agent pembrolizumab as standard of care, or
- eligible to receive single-agent docetaxel as standard of care, or
- advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus nab-paclitaxel as standard of care.
- Age 18 years or older, is willing and able to provide informed consent
- Evidence of measurable disease
- Life expectancy > 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Abbreviated Exclusion Criteria
- History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
- Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
- Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
- History of severe autoimmune disease
- Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1, Single Agent
TTX-030
|
Variable dose and schedule
|
Experimental: Arm 2, Anti-PD-1 Combination
TTX-030 plus pembrolizumab
|
Variable dose and schedule
Dose and schedule per standard of care
|
Experimental: Arm 4, Chemotherapy Combination
TTX-030 plus gemcitabine plus nab-paclitaxel
|
Variable dose and schedule
Dose and schedule per standard of care
Dose and schedule per standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase 2 Dose (RP2D)
Time Frame: 1 cycle (each cycle is 21-28 days)
|
Assess the safety profile, dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TTX-030 when administered intravenously (IV) as a single agent and in combination with agents in specified regimens to subjects with advanced solid tumor malignancies or lymphoma
|
1 cycle (each cycle is 21-28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor activity
Time Frame: Through study completion, an average of 1 year
|
Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens
|
Through study completion, an average of 1 year
|
Maximum Plasma Concentration (Cmax)
Time Frame: Cycles 1-3 (each cycle is 21-28 days)
|
Pharmacokinetics (PK) of TTX-030
|
Cycles 1-3 (each cycle is 21-28 days)
|
CD39 Expression
Time Frame: Through study completion, an average of 1 year
|
Pharmacodynamic (PD) biomarkers relating to mechanism of action and immune responses
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Gemcitabine
- Docetaxel
- Cancer
- Lung Cancer
- Immunotherapy
- Pancreatic Cancer
- Checkpoint Inhibitor
- Pembrolizumab
- PD-1
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Combination Therapy
- Bladder Cancer
- Immuno-oncology
- Nab-paclitaxel
- Monotherapy
- CD39
- Adenosine Pathway
- Relapsed/Refractory Lymphoma
- Prostrate Cancer
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Paclitaxel
- Pembrolizumab
- Gemcitabine
Other Study ID Numbers
- TTX-030-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on TTX-030
-
Trishula Therapeutics, Inc.AbbVieCompletedSolid Tumor, AdultUnited States, Korea, Republic of
-
Merck Sharp & Dohme LLCCompletedHIV Infections | Candidiasis, EsophagealUnited States
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
Wellmarker BioCovanceRecruitingHead and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, Australia
-
TransCode TherapeuticsNot yet recruitingAdvanced Solid Tumor
-
TransCode TherapeuticsRecruitingAdvanced Solid TumorUnited States
-
BayerCompleted
-
Tizona Therapeutics, IncActive, not recruiting
-
BayerCompleted
-
Wex Pharmaceuticals Inc.Completed